troke is leading cause of disability and death in developed countries. Therefore it is of great int t terest to evaluate all factors that could affect the acute phase of stroke and change 30tday mortality and functional outcome. One of these factors is prolonged stress hyperglycemia, which is still not exactly defined and possibly not well treated. Hyperglycemia (blood glucose level >6.1mmol/L or 121 mg/dL) is common in early phase of stroke, even in patients without a previous diagnosis of diabetes melt t litus. It has been found in two thirds of all stroke pat t tients and in almost half of ischemic stroke patients. 3, 4 A recent metatanalyses of prospective and casetcontrol studies confirmed the importance of early stress hypert t glycemia as a predictor of stroke outcome, but debate continues as to whether the effect is independent of pretexisting diagnosis of diabetes or initial stroke severt t ity. It is still not clear what cuttoff value of the mean blood glucose level (MBGL) should be considered safe in diabetic and nontdiabetic patients.
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PATIENTS AND METHODS
We included the data of 630 stroke patients admitted to the Neurological Intensive Care Department within 24 hours of stroke onset in the year 1999 (according to previous medical documentation). 
RESULTS
There were 630 patients (mean age, 73±15.6 years), including 267 men (mean age, 72±14.8 years) and 363 women (75±16.3) admitted to the Neurological Intensive Care Department in the year 1999. Women were 5 years older, but there were no statistically sigt t nificant differences according to age in the patients with stress hyperglycemia.
Crude 30tday shorttterm mortality was 26% (164 patients), while 30tday shorttterm mortality in patients with stress hyperglycemia versus patients without stress hyperglycemia was 25% in nontdiabetic patients and 20% in diabetic patients. There were 101 nontdiabetic patients (16% of all patients) with stress hyperglycemia that died within 30 days of hospitalization versus 46 patients with pretexisting diabetes who died within 30 days (7% of all patients). There were more than double number of nontdiabetic patients versus diabetic patients who died with verified stress hyperglycemia. Statistically significant sex differences were not found so we pooled the data.
There was no statistically significant difference in MBGL between nontdiabetic patients and diabetic pat t tients who did not have stress hyperglycemia and who recovered after stroke. In the group of patients with stress hyperglycemia who died within 30 days of hospit t talization there were statistically significant differences in MBGL between the nontdiabetic patients and the diabetic patients. The first group had a lower MBGL at admission and after 72 hours (P<0.05). Patients in both groups (diabetic and nontdiabetic) varied in MBGL (6.1t36 mmol/L at admission, 6.1t24 mmol/L after 72 hours), but most of them (in both groups) had a MBGL between 6.1t8.0 mmol/L (121t144 mg/dL).
The unadjusted relative risk of inthospital mortalt t ity within 30 days for all stroke patients was 0.68 (95% CI, 0.14t1.9) for nontdiabetic patients and 0.39 (95% CI. 0.27t1.56) for diabetic patients (Figure 1) . The unt t adjusted relative risk of inthospital mortality within 30 days in ischemic stroke patients with MBGL >6.1t8.0 mmol/L (121t144 mg/dL) at admission and after 72 hours was 1.83 (95% CI, 0.41t5.5 ) for nontdiabetic patients and 1.13 (95% CI, 0.78t4.5) for diabetic pat t tients. Nontdiabetic patients with hyperglycemia had a 1.7 higher relative risk of inthospital 30tday mortality than diabetic patients.
DISCUSSION
There are multiple mechanisms of the neuronal damage and bloodtbrain dysfunction in patients with prolonged stress hyperglycemia. Elevated blood glucose is common in the early phase of stroke and is probably mediated by the increased release of the "stress hormones"-cortisol and epinephrine.
Relative insulin deficiency associated with increased lipolysis associated with hyperglycemia diminishes cerebrovascular reactivity. Even in nondiabetic patients stress hyperglycemia may be a marker of deficient glut t cose regulation in individuals with insulin resistance and developing diabetes mellitus. 7 By provoking anaerobic metabolism, lactic acidosis, calcium overload, decreased mitochondrial function and free radical production, hyt t perglycemia may be a cause of the direct membrane lipid peroxidation and cell lysis in the zone of the numbra and penumbra, leading to the direct death of neurons and dysfunction of the bloodtbrain barrier and promoting hemorrhagic infarct conversion. Also, insulin resistance is a very well known indirect risk factor for stroke onset due to increased thrombophilia, endothelial dysfunction and inflammation. 8 Progression of ischemic tissue damage is accompat t nied by increased glutamate secretion and decreased gammataminobutyric acid, mediating the spreading depression of neuronal activity. 8 There is increased act t tivity of neuronal endonucleases and activation of the enzymes of the arachidonic acid cycletcyclooxigenaset2 and 5tlypoxigenase in the first 24 hours. These enzymes are ratetlimiting enzymes in arachidonic acid metabot t lism, leading to production of prostacyclin E2(PGE2) and cysteinetleukotrienes (cystLTs), which are highly potent cerebral vasoconstrictors that lead to enhanced vascular permeability, which induces formation of vat t sogenic edema. 9 Recent MRI studies have confirmed the correlation of penumbral tissue loss and elevated blood glucose levt t els. Using a subcutaneous glucose sensor for 72 hours of glucose monitoring, there was strong evidence of a link between infarct expansion and hyperglycemia, suggesting that hyperglycemia not only determines the initial infarct volume, but also the infarct volume ent t largement. 6 Previous clinical trials have shown that hyperglycet t mia at admission is correlated with a worsened clinical outcome. In nontdiabetic patients stress hyperglycemia was associated with a 3tfold risk for fatal stroke at 30 days and a 1.4tfold risk for poor functional outcome as compared with normoglycemic patients. 11t14 In several thrombolysis trials, hyperglycemia has been found to be associated with decreased odds for neurological imt t provement and also with increased secondary hemort t rhagic events, which leads to speculation that hyperglyt t cemia might be partially responsible for the diminisht t ing beneficial effect of rtPA and early reperfusion. 15, 16 In our study we have shown that there is an unadt t justed relative risk of inthospital mortality within 30 days of 0.68 (95% CI, 0.14t1.9) in nondiabetic patients and of 0.39 (95% CI, 0.22 t1.56 ) in diabetic patients. Nontdiabetic patients with hyperglycemia had a 1.7 higher relative risk of inthospital 28tday mortality than diabetic patients, which correlates with previous studies showing a relative risk about 2.0 times higher in nontdiabetic patients than diabetic patients. All patients who died within 30 days (diabetic and nontdiabetic) varied in MBGL (6.1t36 mmol/L at adt t mission, 6.1t24 mmol/L after 72 hours), but most of them (in both groups) had an MBGL between 6.1t8.0 mmol/L (121t144 mg/dL), which confirms that it is not only important to reduce extremely high MBGL, but also to regulate the moderate hyperglycemia (simit t lar to the results of the Glucose Insulin in Stroke Trialt GISTtUK). 12 The results of this study are limited because relative risk was not adjusted for other risk factors but despite that, a strong and consistent association between adt t mission and 72 hours prolonged hyperglycemia and int t creased 30tday stroke mortality, especially in nontdiat t betic patients suggests that not only high but also modt t erate hyperglycemia is an important risk factor affecting stroke outcome. 11t14 Our results once again demonstrate the need for systematic clinical studies to encourage the restoration of normoglycemia in the acute phase of stroke, with or without applying thrombolysis and/or neuroprotectives in both nontdiabetic and diabetic pat t tients. 15, 16 The European Stroke Initiative (EUSI) and American Stroke Association (ASA) would need to ret t consider their guidelines (EUSI MBGL<10mmol/L, ASA <16.63 mmol/L), so as to reduce 30tday stroke mortality and improve functional outcome.
